Literature DB >> 22942161

Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease.

Hossein Nazari1, Narsing A Rao.   

Abstract

BACKGROUND: To evaluate the correlation of subretinal fluid height with visual acuity (VA) in patients with acute Vogt-Koyanagi-Harada disease (VKH).
METHODS: Clinical information, fundus photographs and spectral domain optical coherence tomography scans from sequential visits of patients with acute VKH treated with oral corticosteroids were analysed. Subretinal fluid (SRF) height and retinal thickness were measured at the fovea. The association between VA and SRF height was evaluated by Spearman correlation analysis.
RESULTS: A total of 12 eyes from 6 consecutive patients were included. SRF height measured 824±508 µm (range 45-1900 µm) at presentation. SRF height correlated with simultaneously measured VA. Initial SRF height did not correlate with resolution time and final VA. Resolution of SRF was attained in 36±24 days (range 10-80 days). The presence of choroidal folds (eight eyes) and multifocal retinal detachment (eight eyes) at presentation correlated with lower initial VA but not with the interval to SRF resolution or with VA at 3-month follow-up.
CONCLUSIONS: Serous retinal detachment resolved in 36±24 days in patients with acute VKH treated with oral corticosteroids. SRF height correlates with VA measured at the same time. The initial SRF, no matter how elevated, does not correlate with VA at 3 months after presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22942161     DOI: 10.1136/bjophthalmol-2012-301857

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.

Authors:  Kotaro Tsuboi; Kei Nakai; Chiharu Iwahashi; Fumi Gomi; Yasushi Ikuno; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-10       Impact factor: 3.117

2.  Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.

Authors:  Stacey Lu; Mehran Taban
Journal:  Digit J Ophthalmol       Date:  2016-06-28

3.  [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].

Authors:  K Wand; S Abraham; D Loos; S Stumpfe; C Lohmann; M Maier; N Feucht
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

4.  Different MicroRNA profiles in Peripheral Blood mononuclear cells from patients with initial-onset and recurrent vogt-Koyanagi-Harada Disease.

Authors:  Kailei Guo; Baiyi Li; Fuhua Yang; Mi Zhang; Guixia Zhao; Xiaomin Zhang
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

5.  [Autofluorescence combined with spectral domain optical coherence tomography for diagnosis and follow-up of acute Vogt-Koyanagi-Harada disease].

Authors:  Shuwei Tian; Jing Yao; Jianming Wang; Jie Zhang; Aiyi Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

6.  Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.

Authors:  Shizhao Yang; Tianyu Tao; Zhaohuai Li; Binyao Chen; Zhaohao Huang; Xiuxing Liu; He Li; Lihui Xie; Wen Feng; Wenru Su
Journal:  Ann Transl Med       Date:  2022-06

7.  Choroidal atrophy and loss of choriocapillaris in convalescent stage of Vogt-Koyanagi-Harada disease: in vivo documentation.

Authors:  Hossein Nazari; Amirhossein Hariri; Zhihong Hu; Yanwei Ouyang; SiriniVas Sadda; Narsing A Rao
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-03-22

Review 8.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.